Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in us community oncology

Clinical Colorectal Cancer

Volumn 11, Issue 4, 2012, Pages 238-246

  Cartwright, Thomas H ^a   Yim, Yeun Mi ^b   Yu, Elaine ^b   Chung, Hsingwen ^a   Halm, Melissa ^a   Forsyth, Michael ^a  

^a McKesson/US Oncology Healthcare Informatics   (United States)

^b GENENTECH INC   (United States)

Author keywords

Patterns of care; Treatment duration

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; BEVACIZUMAB BEYOND PROGRESSION; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE COURSE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; COMMUNITY HEALTH CENTERS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84866726619     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.05.005     Document Type: Article

References (24)

1. R.M. Goldberg, M.L. Rothenberg, E. Van Cutsem The continuum of care: a paradigm for the management of metastatic colorectal cancer Oncologist 12 2007 38 50
2. T. Gruenberger, B. Schuell, H. Puhalia Changes in liver surgery for colorectal cancer liver metastases under neoadjuvant treatment strategies Eur Surg 36 2004 317 321
3. A. Falcone, L. Fornaro, F. Loupakis Optimal approach to potentially resectable liver metastases from colorectal cancer Expert Rev Anticancer Ther 8 2008 1533 1539
4. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
5. E. Van Cutsem, C.H. Köhne, E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
6. G. Masi, E. Vasile, F. Loupakis Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis J Natl Cancer Inst 103 2011 21 30
7. C. Allegra, C. Blanke, M. Buyse End points in advanced colon cancer clinical trials: a review and proposal J Clin Oncol 25 2007 3572 3575
8. National Comprehensive Cancer Network Clinical Colorectal Cancer (NCCN Guidelines): Colon Cancer, version 2 http://www.nccn.org/professionals/ physician-gls/pdf/colon.pdf Accessed January 10, 2011
9. National Comprehensive Cancer Network Clinical Colorectal Cancer (NCCN Guidelines): Rectal Cancer, version 2 http://www.nccn.org/professionals/ physician-gls/pdf/rectal.pdf Accessed January 10, 2011
10. N. Ferrara Molecular and biological properties of vascular endothelial growth factor J Mol Med 77 1999 527 543
11. L.G. Presta, H. Chen, S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
12. C.G. Willett, Y. Boucher, E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [published erratum appears in Nat Med 2004; 10:649] Nat Med 10 2004 145 147
13. F.F. Kabbinavar, J. Hambleton, R.D. Mass Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 2005 3706 3712
14. B.J. Giantonio, P.J. Catalano, N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544
15. A. Grothey, M.M. Sugrue, D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
16. A.L. Cohn, T. Bekaii-Saab, J.C. Bendell Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP) [Abstract] J Clin Oncol 28 15s 2010 284s
17. A. Grothey, T.S. Bekaii-Saab, H. Hurwitz Cumulative exposure to bevacizumab (BV) after progression correlates with increased survival in patients (pts) with metastatic colorectal cancer (mCRC): a time-dependent analysis of the ARIES observational cohort study [Abstract] Eur J Cancer 41 Suppl 1 2011 395
18. T.S. Bekaii-Saab, J.C. Bendell, A.L. Cohn Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): initial results from ARIES, a second BV observational cohort study (OCS) [Abstract] J Clin Oncol 28 15s 2010 284s
19. A Study of Avastin (bevacizumab) Plus Crossover Fluoropyrimidine-based Chemotherapy in Patients With Metastatic Colorectal Cancer (NCT00700102) http://www.clinicatrials.gov Accessed: January 11, 2012
20. Avastin-based regimen extends survival when continued beyond initial treatment in patients with metastatic colorectal cancer http://www.roche.com/ investors/ir-update/inv-update-2012-01-26.htm Accessed: January 30, 2012
21. S. Kopetz, J.L. Abbruzzese Hidden biases in an observational study of bevacizumab beyond progression J Clin Oncol 27 2009 1732 1733
22. G.P. Hess, P.F. Wang, D. Quach Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice J Oncol Pract 6 2010 301 307
23. C. Eng The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development Oncologist 15 2010 73 84
24. J. Tabernero, E. van Cutsem, R. Lakomy Results from VELOUR, a phase III study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer [Abstract] http://www.oncoletter.ch/fileupload/Tabernero.pdf Accessed December 1, 2011